Open AccessRanibizumab in diabetic macular edema
Author(s) -
Claudia M. Krispel,
Murilo Wendeborn Rodrigues,
Xiaoban Xin,
Akrit Sodhi
Publication year - 2013
Publication title -
world journal of diabetes
Language(s) - Uncategorized
Resource type - Journals
ISSN - 1948-9358
DOI - 10.4239/wjd.v4.i6.310
Subject(s) - ranibizumab , medicine , diabetic macular edema , diabetes mellitus , ophthalmology , food and drug administration , bevacizumab , vascular endothelial growth factor , diabetic retinopathy , macular edema , vegf receptors , pharmacology , visual acuity , endocrinology , chemotherapy
By 2050 the prevalence of diabetes will more than triple globally, dramatically increasing the societal and financial burden of this disease worldwide. As a consequence of this growth, it is anticipated that there will be a concurrent rise in the numbers of patients with diabetic macular edema (DME), already among the most common causes of severe vision loss worldwide. Recent available therapies for DME target the secreted cytokine, vascular endothelial growth factor (VEGF). This review focuses on the treatment of DME using the first humanized monoclonal antibody targeting VEGF that has been Food and Drug Administration-approved for the use in the eye, ranibizumab (Lucentis(®)).